396 related articles for article (PubMed ID: 11806330)
1. New drugs and product approvals from 2000.
Taylor SE; Gage TW
Tex Dent J; 2001 Nov; 118(11):1070-81. PubMed ID: 11806330
[No Abstract] [Full Text] [Related]
2. Pharmacogenomics. Going from genome to pill.
Service RF
Science; 2005 Jun; 308(5730):1858-60. PubMed ID: 15976283
[No Abstract] [Full Text] [Related]
3. Prescription for trouble: common drugs, hidden dangers. Tens of people are at risk.
Consum Rep; 2006 Jan; 71(1):34-9. PubMed ID: 16491527
[No Abstract] [Full Text] [Related]
4. When is a medical product too risky? An interview with FDA's top drug official. Interview by Tamar Nordenberg.
Woodcock J
FDA Consum; 1999; 33(5):8-11, 13. PubMed ID: 10522164
[No Abstract] [Full Text] [Related]
5. Pharma's year of trouble and strife.
Frantz S
Nat Rev Drug Discov; 2006 Jan; 5(1):7-9. PubMed ID: 16485339
[No Abstract] [Full Text] [Related]
6. Drug-induced QT interval shortening: an emerging component in integrated assessment of cardiac safety of drugs.
Shah RR; Bjerregaard P; Gussak I
J Electrocardiol; 2010; 43(5):386-9. PubMed ID: 20728017
[No Abstract] [Full Text] [Related]
7. FDA attempting to overcome major roadblocks in monitoring drug safety.
Zielinski SL
J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
[No Abstract] [Full Text] [Related]
8. Hasty approval, more withdrawals.
Prescrire Int; 2005 Aug; 14(78):144. PubMed ID: 16106597
[TBL] [Abstract][Full Text] [Related]
9. Why drugs get pulled off the market.
Meadows M
FDA Consum; 2002; 36(1):11-7. PubMed ID: 11881590
[No Abstract] [Full Text] [Related]
10. Striking the right balance.
Nat Rev Drug Discov; 2006 Nov; 5(11):879. PubMed ID: 17117516
[No Abstract] [Full Text] [Related]
11. Pharmaceutical postmarket review: fact or fiction?
Schanz SJ
Food Drug Law J; 2007; 62(3):493-500. PubMed ID: 17915391
[No Abstract] [Full Text] [Related]
12. Should new drugs be avoided?
Child Health Alert; 2002 Jun; 20():2. PubMed ID: 12096722
[No Abstract] [Full Text] [Related]
13. Adverse drug effects: new information about an old problem.
Miller CA
Geriatr Nurs; 2001; 22(6):336-7. PubMed ID: 11780009
[No Abstract] [Full Text] [Related]
14. Your health in the 21st century. A better safety net.
Rosenberg D
Newsweek; 2005; 145(26A):70-2. PubMed ID: 16375152
[No Abstract] [Full Text] [Related]
15. FDA drug information that never reaches clinicians.
Messerli FH; Bangalore S
N Engl J Med; 2010 Feb; 362(6):562; author reply 563. PubMed ID: 20175300
[No Abstract] [Full Text] [Related]
16. Institute of Medicine's new drug safety report: implications for Canada.
Cassels A
CMAJ; 2006 Dec; 175(12):1515-6. PubMed ID: 17146086
[No Abstract] [Full Text] [Related]
17. Issues in bringing new drugs to the market.
Tracey WR
Science; 2005 Dec; 310(5753):1425-6; author reply 1425-6. PubMed ID: 16329172
[No Abstract] [Full Text] [Related]
18. Hiding behind agency discretion: the Food and Drug Administration's personal use drug importation policy.
Reichertz PS; Friend MS
Cornell J Law Public Policy; 2000; 9():493-521. PubMed ID: 11067734
[No Abstract] [Full Text] [Related]
19. Regulating the fate of pharmaceutical drugs: a new prescription for the environment.
Nidel CT
Food Drug Law J; 2003; 58(1):81-101. PubMed ID: 12739585
[No Abstract] [Full Text] [Related]
20. International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2005 Oct; 70(202):61134-5. PubMed ID: 16237860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
